Vitafoam Nigeria Plc, a leading manufacturer of foam and polyurethane-based products, has released its Q3 2026 financial statements, showcasing a significant improvement in profitability. The company's turnover increased by 7.47% to N91.21 billion, driven by growth in its product lines, including mattresses, pillows, and furniture components. This growth has been a result of Vitafoam's strategic expansion and diversification efforts over the years. The company has been in operation since 1963 and has established itself as a major player in Nigeria's industrial sector.
Vitafoam's cost of sales increased by 3.61% to N58.05 billion, a relatively lower growth rate compared to turnover. This improvement in gross operating efficiency contributed to a 17.26% increase in operating profit, which rose to N21.67 billion. Despite a 15.33% increase in operating expenses, the company's operating profit margin improved from 21.78% to 23.76%. Additionally, Vitafoam's finance cost declined by 72.42% to N1.34 billion, driven by reduced financing pressure. This significant decrease in finance cost has positively impacted the company's overall financial performance.
The company's profit before tax grew by 50.15% to N20.76 billion, driven by improved operating performance and reduced financing costs. However, tax expense increased by 60.12% to N7.13 billion, partly moderating the growth in profit after tax. Despite this, Vitafoam's profit after tax increased by 45.42% to N13.63 billion, while total comprehensive income rose by 36.45% to N12.45 billion. The company's PAT margin improved from 11.05% to 14.95%, reflecting its enhanced profitability. These improvements demonstrate Vitafoam's ability to manage its finances effectively.
Vitafoam's Statement of Financial Position at Q3 2026 shows a significant expansion in its asset base. Total assets increased by 21.44% to N70.16 billion, driven by a 28.20% growth in current assets to N53.23 billion. Non-current assets rose moderately by 4.17% to N16.92 billion. The company's net assets strengthened by 35.73% to N44.11 billion, while retained earnings recorded a strong 61.39% increase to N34.67 billion. This growth in assets and net assets reflects Vitafoam's strategic investments and expansion efforts.
Vitafoam's financial strength and solvency position improved in Q3 2026. The debt ratio declined by 15.14% to 37.12%, indicating a lower proportion of assets financed by debt. The Total Debt-to-Equity ratio fell by 24.08% to 0.59x, suggesting reduced financial leverage and a stronger equity cushion. The equity ratio increased by 11.77% to 62.88%, reflecting shareholders' funds financing a larger proportion of the company's assets. These improvements demonstrate Vitafoam's enhanced financial stability.
Vitafoam's profitability ratios also showed significant improvements in Q3 2026. The EBIT margin increased by 9.11% to 23.76%, while the PBT margin rose substantially by 39.71% to 22.76%. The effective tax rate increased to 52.28%, but the Cost of Sales-to-Turnover ratio declined by 3.59% to 63.64%. Returns to shareholders and assets strengthened, with ROE increasing by 7.14% to 30.90% and ROA rising by 19.75% to 19.43%. These improvements reflect Vitafoam's enhanced operational efficiency and profitability.
Analysts are expecting Vitafoam's Q4 unaudited earnings reports to provide further insights into the company's financial performance. With a beta of 0.87, Vitafoam's historical share-price volatility has been below the broader market benchmark. The company's shares are currently trading at N194.00, with an estimated fair value of N135.99. As one of Nigeria's long-established manufacturing companies, Vitafoam's improved financial performance is expected to have a positive impact on the country's industrial sector.
Key points
- Vitafoam Nigeria Plc's Q3 2026 financials reveal a 45.42% increase in profit after tax.
- The company's debt ratio declined by 15.14% to 37.12%, indicating improved financial strength and solvency.
- Vitafoam's profitability ratios, including EBIT margin and ROE, showed significant improvements in Q3 2026.
